Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024

被引：0

作者：

Antunes, Liliana ^{[1
]}

Rojas-Castro, Madelyn ^{[1
]}

Lozano, Marcos ^{[2
,3
]}

Martinez-Baz, Ivan ^{[3
,4
]}

Leroux-Roels, Isabel ^{[5
,6
,7
]}

Borg, Maria-Louise ^{[8
]}

Oroszi, Beatrix ^{[9
]}

Fitzgerald, Margaret ^{[10
]}

Duerrwald, Ralf ^{[11
]}

Jancoriene, Ligita ^{[12
]}

Machado, Ausenda ^{[13
]}

Petrovic, Goranka ^{[14
]}

Lazar, Mihaela ^{[15
]}

Souckova, Lenka ^{[16
]}

Bacci, Sabrina ^{[17
]}

Howard, Jennifer ^{[1
]}

Verdasca, Nuno ^{[18
]}

Basile, Luca ^{[19
]}

Castilla, Jesus ^{[3
,4
]}

Ternest, Silke ^{[5
]}

Dziugyte, Ausra ^{[8
]}

Turi, Gergo ^{[9
]}

Duffy, Roisin ^{[10
]}

Hackmann, Carolin ^{[11
]}

Kuliese, Monika ^{[20
]}

Gomez, Veronica ^{[13
]}

Makaric, Zvjezdana Lovric ^{[14
]}

Marin, Alexandru ^{[21
]}

Husa, Petr ^{[16
]}

Nicolay, Nathalie ^{[17
]}

Rose, Angela M. C. ^{[1
]}

VEBIS SARI VE network team

机构：

[1] EpiConcept, Paris, France

[2] Inst Hlth Carlos III, Natl Ctr Epidemiol, Madrid, Spain

[3] Consortium Biomed Res Epidemiol & Publ Hlth, Madrid, Spain

[4] Inst Salud Publ Navarra IdiSNA, Pamplona, Spain

[5] Ghent Univ Hosp, Dept Infect Control, Ghent, Belgium

[6] Univ Ghent, Ghent Univ Hosp, B-9000 Ghent, Belgium

[7] Ghent Univ Hosp, Ghent, Belgium

[8] Hlth Promot & Dis Prevent, Infect Dis Prevent & Control Unit IDCU, Msida, Malta

[9] Semmelweis Univ, Epidemiol & Surveillance Ctr, Natl Lab Hlth Secur, H-1085 Budapest, Hungary

[10] Hlth Protect Surveillance Ctr HPSC, Hlth Serv Execut, Dublin, Ireland

[11] Robert Koch Inst, Natl Reference Ctr Influenza, Berlin, Germany

[12] Vilnius Univ, Inst Clin Med, Fac Med, Clin Infect Dis & Dermatovenerol, Vilnius, Lithuania

[13] Natl Hlth Inst Doutor Ricardo Jorge, Dept Epidemiol, Lisbon, Portugal

[14] Croatian Inst Publ Hlth, Zagreb, Croatia

[15] Cantacuzino Natl Mil Med Inst Res Dev, Bucharest, Romania

[16] Masaryk Univ, Univ Hosp Brno, Brno, Czech Republic

[17] European Ctr Dis Prevent & Control, Stockholm, Sweden

[18] Natl Hlth Inst Doutor Ricardo Jorge, Dept Infect Dis, Lisbon, Portugal

[19] Generalitat Catalonia, Publ Hlth Agcy Catalonia, Subdirectorate Gen Surveillance & Response Publ Hl, Barcelona, Spain

[20] Lithuanian Univ Hlth Sci, Dept Infect Dis, Kaunas, Lithuania

[21] Dr Victor Babes Clin Hosp Infect & Trop Dis, Bucharest, Romania

来源：

INFLUENZA AND OTHER RESPIRATORY VIRUSES | 2025年 / 19卷 / 03期

关键词：

case-control study; elderly; severe acute respiratory infections (SARI); test-negative design; vaccine effectiveness;

D O I：

10.1111/irv.70081

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (>= 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at 60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.

引用

页数：7

共 25 条

[1] Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024
Merdrignac, Lore
Delaunay, Charlotte Laniece
Verdasca, Nuno
Vega-Piris, Lorena
O'Donnell, Joan
Seve, Noemie
Trobajo-Sanmartin, Camino
Buda, Silke
Hooiveld, Mariette
Rodrigues, Ana Paula
Turi, Gergo
Latorre-Margalef, Neus
Mlinaric, Ivan
Lazar, Mihaela
Maurel, Marine
Castrillejo, Daniel
Bennett, Charlene
Rameix-Welti, Marie-Anne
Martinez-Baz, Ivan
Duerrwald, Ralf
Meijer, Adam
Melo, Aryse
Oroszi, Beatrix
Hagey, Tove Samuelsson
Filipovic, Sanja Kurecic
Dijkstra, Frederika
Gomez, Veronica
Bacci, Sabrina
Kaczmarek, Marlena
Kissling, Esther
INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2024, 18 (11)
[2] Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study
Nunes, Baltazar
Humphreys, James
Nicolay, Nathalie
Braeye, Toon
Van Evercooren, Izaak
Hansen, Christian Holm
Moustsen-Helms, Ida Rask
Sacco, Chiara
Fabiani, Massimo
Castilla, Jesus
Martinez-Baz, Ivan
Meijerink, Hinta
Machado, Ausenda
Soares, Patricia
Ljung, Rickard
Pihlstrom, Nicklas
Nardone, Anthony
Bacci, Sabrina
Monge, Susana
EXPERT REVIEW OF VACCINES, 2024, 23 (01) : 1085 - 1090
[3] Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024
Antunes, Liliana
Mazagatos, Clara
Martinez-Baz, Ivan
Naesens, Reinout
Borg, Maria-Louise
Petrovic, Goranka
Fatukasi, Terra
Jancoriene, Ligita
Machado, Ausenda
Oroszi, Beatrix
Husa, Petr
Lazar, Mihaela
Duerrwald, Ralf
Howard, Jennifer
Melo, Aryse
Perez-Gimeno, Gloria
Castilla, Jesus
Bernaert, Eva
Dziugyte, Ausra
Makaric, Zvjezdana Lovric
Fitzgerald, Margaret
Mickiene, Aukse
Gomez, Veronica
Turi, Gergo
Souckova, Lenka
Marin, Alexandru
Tolksdorf, Kristin
Nicolay, Nathalie
Rose, Angela M. C.
INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2024, 18 (08)
[4] Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity-IVY Network, 26 Hospitals, 18 October 2023-9 March 2024
Ma, Kevin C.
Surie, Diya
Lauring, Adam S.
Martin, Emily T.
Leis, Aleda M.
Papalambros, Leigh
Gaglani, Manjusha
Columbus, Christie
Gottlieb, Robert L.
Ghamande, Shekhar
Peltan, Ithan D.
Brown, Samuel M.
Ginde, Adit A.
Mohr, Nicholas M.
Gibbs, Kevin W.
Hager, David N.
Saeed, Safa
Prekker, Matthew E.
Gong, Michelle Ng
Mohamed, Amira
Johnson, Nicholas J.
Srinivasan, Vasisht
Steingrub, Jay S.
Khan, Akram
Hough, Catherine L.
Duggal, Abhijit
Wilson, Jennifer G.
Qadir, Nida
Chang, Steven Y.
Mallow, Christopher
Kwon, Jennie H.
Parikh, Bijal
Exline, Matthew C.
Vaughn, Ivana A.
Ramesh, Mayur
Safdar, Basmah
Mosier, Jarrod
Harris, Estelle S.
Shapiro, Nathan, I
Felzer, Jamie
Zhu, Yuwei
Grijalva, Carlos G.
Halasa, Natasha
Chappell, James D.
Womack, Kelsey N.
Rhoads, Jillian P.
Baughman, Adrienne
Swan, Sydney A.
Johnson, Cassandra A.
Rice, Todd W.
CLINICAL INFECTIOUS DISEASES, 2024,
[5] Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study
Monge, Susana
Humphreys, James
Nicolay, Nathalie
Braeye, Toon
Van Evercooren, Izaak
Hansen, Christian Holm
Emborg, Hanne-Dorthe
Sacco, Chiara
Mateo-Urdiales, Alberto
Castilla, Jesus
Martinez-Baz, Ivan
de Gier, Brechje
Hahne, Susan
Meijerink, Hinta
Kristoffersen, Anja Brathen
Machado, Ausenda
Soares, Patricia
Nardone, Anthony
Bacci, Sabrina
Kissling, Esther
Nunes, Baltazar
INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2024, 18 (04)
[6] Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024
Huiberts, Anne J.
Hoeve, Christina E.
de Gier, Brechje
Cremer, Jeroen
van der Veer, Bas
de Melker, Hester E.
van de Wijgert, Janneke H. H. M.
van den Hof, Susan
Eggink, Dirk
Knoll, Mirjam J.
EUROSURVEILLANCE, 2024, 29 (10)
[7] XBB.1.5 mRNA COVID-19 vaccine protection against inpatient or emergency department visits among adults infected with SARS-CoV-2 JN.1 and XBB-lineage variants
Levy, Matthew E.
Chilunda, Vanessa
Heaton, Phillip R.
Mckeen, Deran
Goldman, Jason D.
Davis, Richard E.
Schandl, Cynthia A.
Glen, William B.
Mcewen, Lisa M.
Cirulli, Elizabeth T.
Wyman, Dana
Dei Rossi, Andrew
Dai, Hang
Isaksson, Magnus
Washington, Nicole L.
Basler, Tracy
Tsan, Kevin
Nguyen, Jason
Ramirez, Jimmy
Sandoval, Efren
Lee, William
Lu, James
Luo, Shishi
FRONTIERS IN IMMUNOLOGY, 2025, 16
[8] Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial
Gayed, Juleen
Bangad, Vishva
Xu, Xia
Mensa, Federico
Cutler, Mark
Tureci, Ozlem
Sahin, Ugur
Modjarrad, Kayvon
Swanson, Kena A.
Anderson, Annaliesa S.
Gurtman, Alejandra
Kitchin, Nicholas
VACCINES, 2024, 12 (07)
[9] STAR LIGHT Study: XBB.1.5 COVID-19 mRNA Vaccines Boost Systemic but Not Mucosal Immunity Against the SARS-CoV-2 JN.1 Variant in Patients with Chronic Liver Disease
Woelfel, Simon
Junker, Daniel
Bergamin, Irina
Meyer-Herbon, Pamela
Stillhard, Roman
Graf, Nicole
Leinenkugel, Georg
Dutschler, Joel
Koenig, Marius
Kammerlander, Livia
Hauptle, Rahel
Zwyssig, Sarah
Krieger, Claudia
Truniger, Samuel
Koller, Seraina
Metzger-Peter, Katline
Frei, Nicola
Albrich, Werner C.
Friedrich, Matthias
Bernsmeier, Christine
Niess, Jan Hendrik
Korte, Wolfgang
Burgi, Justus J.
Dulovic, Alex
Schneiderhan-Marra, Nicole
Semela, David
Brand, Stephan
VACCINES, 2024, 12 (11)
[10] Systemic and mucosal immune responses against the SARS-CoV-2 XBB.1.5, EG.5.1, and BA.2.86 lineages induced by monovalent XBB.1.5-adapted COVID-19 mRNA vaccines in patients with inflammatory bowel disease
Woelfel, Simon
Dueschlerl, Joel
Junker, Daniel
Konig, Marius
Leinenkugel, Georg
Graf, Nicole
Krieger, Claudia
Truniger, Samuel
Franke, Annett
Koller, Seraina
Metzger-Peter, Katline
Oberholzer, Melanie
Frei, Nicola
Geissler, Nora
Schaub, Peter
Albrich, Werner C.
Friedrich, Matthias
Niess, Jan Hendrik
Schneiderhan-Marra, Nicole
Dulovic, Alex
Korte, Wolfgang
Burgi, Justus J.
Brand, Stephan
SWISS MEDICAL WEEKLY, 2024, 154 : 11S - 11S

← 1 2 3 →